PDF   Print   View All
February 07, 2005
Promising Effects In Bird Populations To Be Expanded based on WHO/UN Findings

….New Goal is Slow Disease, Minimize Risks; Eradication Looks Unlikely.

Philadelphia, PA, Monday, February 07, 2005:
Hemispherx Biopharma, Inc. (AMEX: HEB) announced today further studies in collaboration with U.S. government sponsored laboratories to determine the potential antiviral activity of Alferon N against avian influenza. On February 5, 2005, members of the World Health Organization (WHO) and the U.N. Food and Agriculture Organization characterized in Asia certain conditions described as “the beginnings of the avian flu pandemic,” as quoted in the N.Y. Times.

Previous peer reviewed experimental research conducted has shown that low doses of Alferon N, the only natural alpha IFN cocktail available in the U.S.A., added to the water and food supply of the bird population reduced death rate as well as produced healthier weight compared to birds that received placebo. Typically, birds in close quarters being raised as a poultry crop are exposed to various stressful conditions, which include outbreaks of viral infections and makes them more susceptible to disease. This well-controlled study demonstrated that Alferon N can both decrease the morbidity and death rates of birds living under these conditions as well as produce a larger bird when trace amounts of Alferon are added to the food supply. The published abstract can be found in Archlvum Immunologiac et Therapiae Experimentalls, 1993, 41, 209-212,

The Canadian Broadcasting System noted that a mutant form of bird flu virus could kill as many as 7 million people worldwide and infect nearly one-third of the world’s population, according to the World Health Organization’s projections. The H5N1 avian flu virus has killed more than 41 of the 54 infected people in Thailand and Vietnam this year and forced Asian governments to kill tens of millions of poultry in an effort to prevent the spread of the disease to other birds and man. Infectious disease experts fear the virus will soon mutate within a pig or some other animal, which harbors both human and avian forms of the flu virus. If so, the virus could gain the ability to pass easily from person to person and no one would be immune. Earlier today, researchers at the Center for Infectious Disease Research called the events a “Clarion call” for the world “to prepare for a potential global pandemic along the lines of the 1918-1919 flu that killed tens of millions of people.”

About Alferon N
Alferon N® (Interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high purified alpha interferon. It is the only natural-source, multispecies alpha interferon currently sold in the U.S. for the treatment of refractory papilloma infections (HPV) and is also approved for sale by various regulatory agencies worldwide including Singapore and Hong Kong.

About Hemispherx
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Its flagship products include Alferon N® and the experimental immunotherapeutics/antivirals Ampligen® and Oragens™. These novel proteins, approved for a category of STD infection, and experimental nucleic acids are being developed for globally important chronic viral diseases and disorders of the immune system including HPV, HIV, CFS and Hepatitis. Recently, clinical trials in co-infected patients (HIV and HCV) were announced in Spain. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has approximately 270 patents comprising its core intellectual property estate, a fully commercialized product (Alferon N®) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Hemispherx Biopharma, Inc.,
Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6369

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including AmpligenÒ and Oragensä) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Only Clinical Studies under well-controlled conditions can establish efficacy and safety of any product. Clinical trials for other potential indications of the approved biologic AlferonÒ do not imply that the product will ever be specifically approved commercially for these other treatment indication.